Bivalirudin and eptifibatide's bleeding risks are evaluated in study

08/22/2013 | InternalMedicineNews.com (free registration)

Researchers at Mount Auburn Hospital in Massachusetts found that angioplasty patients who received bivalirudin had fewer but more severe bleeding episodes than those treated with eptifibatide. Among 345 patients who received eptifibatide, 20 had bleeding events, while 10 events were reported among 660 patients in the bivalirudin group, and in each group, seven of the episodes were considered severe.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA